VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
A legfontosabb adatok
- Ki végzi
- Ottawa Hospital Research Institute
- Hol
- Kanada3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 120 fő, tervezett
- Kezdés
- 2024. nov. 4.
- Várható befejezés
- 2028. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Rivaroxaban 10 MG
- Placebo control
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with active genitourinary cancer who are starting systemic therapy. It tests low dose rivaroxaban against placebo to prevent blood clots.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Active cancer of the bladder, testis, ureter/renal pelvis, kidney, urethra or penis. People with prostate cancer cannot join.
- Korábbi kezelés
- Must be starting systemic therapy (chemotherapy, targeted therapy such as tyrosine kinase inhibitors and antiangiogenic therapy, or immunotherapy). The planned treatment must last at least 8 weeks.
A részvétel fő kizáró okai
- Needing blood thinners for another reason for the whole study
- Ongoing bleeding that does not stop, a chronic bleeding disorder, or past conditions with higher bleeding risk such as stroke
- Severe kidney problems (creatinine clearance <30 mL/min) or severe liver disease
- Low platelet count (< 50 x 109/L) or life expectancy under 6 months
- Pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Patients who are starting systemic therapy for active GU cancer (bladder, testis, ureter/renal pelvis, kidney, urethral, penile) except for prostate cancer
- Age ≥ 18
- Eligible systemic therapies include chemotherapy, targeted therapies (tyrosine kinase inhibitors and antiangiogenic therapy), and immunotherapies
- Patients must be initiating systemic therapy with a minimum planned treatment duration of 8 weeks
Ki nem vehet részt
- Concomitant use of dual antiplatelet therapy (two antiplatelet medications oncomitantly)
- Concomitant use of strong inducers or inhibitors of CYP3A4 or glycoprotein-P (known interaction with rivaroxaban)
- History of condition at increased bleeding risk including, but not limited to:; cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the previous 4 weeks
- Known allergies to rivaroxaban
- Ongoing refractory bleeding that may be exacerbated by rivaroxaban
- Severe liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis)
- Chronic hemorrhagic disorder
- Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault))
- Thrombocytopenia < 50 x 109/L
- Pregnancy (if child bearing age under 50 and sexually active, documentation of use of effective contraception or negative B- HCG is required)
- Anticoagulation (prophylactic or therapeutic dosing) required for another indication for entire duration of study
- Life expectancy under 6 months
- Patient is breastfeeding or lactating
- Inability to adhere to protocol or obtain consent
- Patients may be excluded from the study for other reasons, at the investigator's discretion
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy). Blood clots cause pain, may require hospitalization and invasive testing, and in some cases cause death. In fact, blood clots are one of the leading causes of death in patients with cancer. Furthermore, patients who develop a blood clot require medication to thin the blood for a prolonged (sometimes indefinite) period of time, and this can disrupt other important cancer treatments. Studies have shown that using low dose blood thinners to prevent blood clots during systemic therapy is effective in some patients with cancer. However very few patients in these studies had genitourinary cancers, therefore physicians in Canada are not sure if recommending blood thinners to patients with genitourinary cancers is useful or safe. Safety is a primary concern because blood thinners may cause bleeding, and patients with genitourinary cancers may have higher risk of bleeding than patients with other types of cancer. The investigators hypothesize that blood thinners are effective and safe for reducing blood clots in patients with genitourinary cancers. The objective of this study is to determine if a large clinical trial testing the effectiveness and safety of low dose blood thinners for preventing blood clots in patients with genitourinary cancers receiving systemic therapy is feasible.
A vizsgálat 2 csoportja
- RivaroxabanA vizsgált kezelés
Participants receiving study drug (Rivaroxaban)
Kezelés: Rivaroxaban 10 MG
- ControlPlacebo, összehasonlításként
Participants receiving matched placebo
Kezelés: Placebo control
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Prevention of Thromboembolism With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. november 12.